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The molecular understanding of phenotypes caused by drugs in humans is essential for elucidating
mechanisms of action and for developing personalized medicines. Side effects of drugs (also known
as adverse drug reactions) are an important source of human phenotypic information, but so far
research on this topic has been hampered by insufficient accessibility of data. Consequently, we
have developed a public, computer-readable side effect resource (SIDER) that connects 888 drugs to
1450 side effect terms. It contains information on frequency in patients for one-third of the drug–side
effect pairs. For 199 drugs, the side effect frequency of placebo administration could also be
extracted. We illustrate the potential of SIDER with a number of analyses. The resource is freely
available for academic research at http://sideeffects.embl.de.
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Introduction
Side effects are phenotypic responses of the human organism
to drug treatment. In recent years, side effects have become an
important subject of research in the pharmaceutical industry,
which is interested in predicting the possible side effects
of drug candidates based on, for example, the binding
fingerprint, chemical structure and other properties of the
drug candidate (Krejsa et al, 2003; Bender et al, 2007; Fliri et al,
2007). Side effects can also be used to predict novel
drug–target interactions and might be utilizable for drug
re-purposing (Campillos et al, 2008).
Pharmacological andmedical researchwould greatly benefit
from the integration of side effect data with other emerging
public resources in chemical biology. For example, the
National Institutes of Health Molecular Libraries Roadmap
Initiative has led to the creation of the PubChem repository of
chemical compounds (Wheeler et al, 2007). Data on cellular
phenotypes in response to chemicals are stored in PubChem
BioAssay and ChemBank (Seiler et al, 2008). Other databases,
such as DrugBank, the PSDP Ki database and BindingDB,
contain binding information (Roth et al, 2000; Liu et al, 2007;
Wishart et al, 2008). As public databases of protein–chemical
interactions are beginning to grow, there is hope that pharma-
cology may be transformed by the application of large-scale
computational methods in the same way that biology has been
(Kuhn et al, 2008). However, there is currently no public
database of drug side effects that makes these important data
readily available for analysis and research.
To ameliorate this situation, we have compiled package
inserts from several public sources, in particular, from the US
Food and Drug Administration (FDA), in the form of either
Structured Product Labeling (SPL) or Portable Document
Format (PDF) documents. SPL is a dedicated electronic format
for package inserts and is thus more amenable to extracting
information. We used text mining to solve the cumbersome
task of extracting side effects from the differently formatted,
human-readable labels (see Materials and methods). The
standardized Coding Symbols for a Thesaurus of Adverse
Reaction Terms (COSTART), which are part of the Unified
Medical Language System (UMLS) Metathesaurus, were used
as the basic lexicon of side effects. To facilitate linking to other
databases and reuse for research, we havemapped drug names
to PubChem identifiers.
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Results and discussion
Side effect resource (SIDER) contains 62 269 drug–side effect
pairs and covers a total of 888 drugs and 1450 distinct side
effects. Altogether, 70% of drugs have between 10 and 100
different side effects (Figure 1A). There is an under-represen-
tation of drugs with few side effects, whereas 55% of all side
effects occur foro10 drugs (Figure 1B). In all, 33% of all side
effects occur for 10–100 drugs; 12% of all side effects occur for
4100 drugs. Labels for 79% of the drugs were available in SPL
format, and 75% in PDF (i.e., 55% of the drugs are available in
both formats). In total, 798 of these drugs are FDA-approved;
the remaining 90 drugs have either been previously approved
but were since withdrawn from the market (like cerivastatin
(Lipobay/Baycol)), or are marketed outside the United States
(like gliclazide).
We group the 888 drugs in SIDER by their drug class, that is,
the main anatomical group of their indication area as derived
from first-level Anatomical Therapeutic Chemical Classifica-
tion System (ATC) code, and analyze how specific the side
effects are to drug classes. It becomes apparent that most side
effects can occur for more than one drug class (Figure 2A). In
fact, even when excluding drugs that belong to more than one
drug class, only 347 out of 1344 side effects (25.8%) occur in
only one drug class. This overlap of side effects between drugs
from different anatomical classes points to commonmolecular
mechanisms for drugs of different classes or multiple
anatomical effects of the same drug. That is, on one hand,
drugs can have off-targets in other tissues and, on the other
hand, the main targets themselves can be expressed in
different tissues or have effects in other tissues (Liebler and
Guengerich, 2005). At the level of individual drugs, side effect
similarity has been found to be predictive of common drug
targets. For example, the proton pump inhibitor rabeprazole
(indicated against stomach ulcers) and the dopamine receptor
agonist pergolide (previously used to treat Parkinson’s
disease) share many side effects (Supplementary Figure S1).
Indeed, rabeprazole has been shown to bind to dopamine
receptors (Campillos et al, 2008).
At the level of drug classes, common side effects reveal
important information as they can point, for example, to
shared underlying mechanisms of action. We therefore
calculated which side effects were most over-represented per
drug class using Fisher’s exact test for a non-redundant set of
drugs (at a q-value cutoff of 0.05, see Supplementary
Information). For 12 out of 14 drug classes, we find
significantly over-represented side effects (Figure 2B, see
Supplementary Table 3 for a full list of over-represented side
effects and their q-values). To investigatewhich side effects are
related to the primary indication area of the drug and which
ones occur in other areas of the body, we take into account
anatomical classes as defined in the COSTART ontology and
assign anatomical classes to drug classes (see Supplementary
Table 2). We find that 28% of all over-represented side effects
are directly related to the anatomical region of the drug class,
while 43% are related to a different anatomical class, and thus
represent the phenotypic expression of off-target and off-tissue
effects. (For the remaining 29%, either drugs or side effects
have no corresponding anatomical class, see Supplementary
Table 3.) Of the ten drug classes that have a corresponding
anatomical class, eight have one or more significantly over-
represented side effects outside their anatomical classes. In all
cases in which over-represented side effects have been found,
this is highly significant, with P-values below 0.01 when the
assignments between drugs and drug classes are randomized
(controlling for multiple testing by Bonferroni correction). For
example, cardiovascular drugs also cause dizziness, impo-
tence (erectile dysfunction) and weakness. Dizziness and
weakness can be probably attributed to a decreased blood
pressure caused bymedications like b-blockers. Impotence has
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Figure 1 Statistics of the database. (A) The number of side effects is counted for each drug and the number of drugs is plotted versus the number of side effects per
drug. For example, there are about 200 drugs with at least 100 side effects. (B) Similar to A, the number of drugs per side effects is plotted.
Figure 2 Analysis of side effects. (A) Overview of the different categories of drugs. Drugs are grouped by their drug class. The number of shared and unique drugs and
side effects is shown for each class. (Some drugs, e.g., aspirin, have more than one anatomical class assigned to them.) (B) Using Fisher’s exact test, over-represented
side effects were determined for each category. A few over-represented medical concepts might describe indications for the drugs (e.g., ‘cancer’) that were not caught by
our filtering mechanisms (see Materials and methods). These concepts are marked with an asterisk. (C) Associations between drug classes and anatomical classes of
side effects are shown (see Supplementary Information). Positive values indicate an association between a drug and an anatomical class. Negative values represent an
under-representation, for example, drugs indicated for disorders of the blood system cause few sensory side effects.
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Shared between ATC codes Unique to one ATC code
ATC category (abbreviated) Number of drugs Number of side effects
A
A
B
C
alimentary tract and metabolism
B blood and blood-forming organs
C cardiovascular system
D dermatologicals
G genitourinary system and sex hormones
H systemic hormonal preparations
J antiinfectives for systemic use
L antineoplastic and immunomodulating agents
M musculo-skeletal system
N nervous system
P antiparasitic products
R respiratory system
S sensory organs
V various
0 50 100 150 200 0 250 500 750 1000 1250
Top three over-represented side effects
from any anatomical class from a different anatomical class
A porphyria cutanea tarda, bloating no over-represented side effects
B venous thrombosis, intracranial hemorrhage venous thrombosis
C postural hypotension, AV block, dizziness dizziness, impotence, weakness
D contact dermatitis, burning sensation, erythema burning sensation
G breast tenderness, ovarian cancer, nipple discharge global amnesia
H aseptic necrosis no over-represented side effects
J neutropenia, pseudomembranous colitis, thrombocytopenia n/a
L constitutional symptoms, alopecia, cancer* n/a
M peptic ulcer, nephrotic syndrome, gastrointestinal hemorrhage peptic ulcer, nephrotic syndrome, gastrointestinal hemorrhage
N increased salivation, hallucinations, ataxia hiccup, weight loss, urinary urgency
P no over-represented side effect n/a
R nasal septum perforation, dysphonia, viral infection dysphonia, viral infection, hoarseness
S keratitis, myasthenia gravis, blepharitis myasthenia gravis
V no over-represented side effects n/a
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Nonspecific disorders
Ophthalmic and sensory disorders
Respiratory disorders
Nervous disorders
Musculo-skeletal disorders
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been found to be a side effect of several kinds of cardiovascular
drugs such as calcium channel inhibitors, angiotensin II
antagonists, non-selective b-blockers and diuretics (Shiri
et al, 2007). The occurrence of erectile dysfunction for non-
selective b-blockers has been explained with their action on a-
adrenergic receptors in penile tissue (Lue, 2000), thus
providing an example of closely related off-targets in different
tissues. In conclusion, almost all drug classes have signifi-
cantly over-represented side effects, some of which even point
to a shared action of drug of the same therapeutic area on
targets outside the intended indication area.
To get a global overview of the anatomical distribution of the
side effects of drug classes, we calculate association scores
(see Supplementary Information) between drug classes and
anatomical classes. We find that drugs from all drugs classes
cause side effects also in anatomical classifications that do not
correspond to the respective indication area (Figure 2C);
however, the extent to which this occurs is not the same for all
drug classes. Some drug classes are very specific, especially
those applied topically like dermatologicals (ATC code D) and
sensory organ drugs (S), whereas others aremore spread, such
as antineoplastic and immunomodulating drugs (L).
By automatically interpreting the text and tables on package
inserts, we were able to obtain information on the frequencies
of the side effects for more than half of the drugs (500 of 888),
either as a general frequency range (e.g., ‘frequent’) or as an
exact frequency (e.g., ‘3.1%’, see Materials and methods). We
determined by manually inspection of 20 randomly chosen
examples that for half of the remaining drugs, the available
labels do not contain any frequency information and thus even
a human expert could not derive such information. None-
theless, frequency information could be deduced for 23 631
drug–side effect pairs (38% of all pairs, Figure 3A). Exact
frequencies could be extracted from tables in SPL documents
for 6448 (27%) of all pairs with frequency information by
analyzing the content of the table caption and rows to deduce
the format of the table (e.g., percentage or number of cases).
The median frequency in patients of ‘frequent’ side effects
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Figure 3 (A) For the different side effect frequency classes, the number of drug–side effect pairs is shown. For a fraction of the side effects an exact frequency (e.g.,
‘3%’) is known, whereas for others only the general frequency class (e.g., ‘frequent’) is given in package inserts. When an exact frequency is given on the labels, the
corresponding frequency of the side effect in the control (placebo) group is often also available. (B) The number of drug–side effect pairs with specific frequencies is
counted. Exact frequency ranges are in many cases only given for side effects occurring in at least 1% of the patients, therefore the first bin (o1%) of the histogram has a
lower abundance than the second bin (1–2%). (C) Frequencies obtained from the administration of drug and placebo during clinical trials are compared. In panels C and
D, the blue line stands for equal frequency and the red line for side effects that are twice as frequent after drug treatment than in the control group. (D) For each side
effect, the median frequency in drug and placebo administration is computed. The area of the circles corresponds to the number of drugs with the side effect and
available placebo information. (See Supplementary Figure S2 for adapted versions of C and D that resolve the cloud of points near the origin.).
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(occurring in 41% of patients) is 5%. Thus, it is reassuring
that even frequent side effects mostly occur in aminority of the
patients (Figure 3B).
The SPL documents often also contain information about
the frequency of the side effects when a placebo had been
administered during clinical trials. Frequency information is
available for 3426 placebo–side effect pairs (53% of the pairs
with exact frequency information and 14% of all drug–side
effect pairs). To illustrate the utilization of placebo informa-
tion, we compared the frequencies reported during clinical
trials for drug and placebo administration (Figure 3C). The low
fraction (14%) of side effects that are more frequent for
placebo than drug administration reflects that side effects are
generally only reported if the patients receiving the drug have a
higher frequency than those receiving placebo. The main
purpose of this limitation is to filter out the symptoms (or
phenotypes) that occur in all patients with a given medical
condition, regardless of actual treatment. If a symptom occurs
at the expected rate for the population or if it is related to the
pre-existing condition and not to drug treatment, then the
frequency will be the same in both groups. However, it would
be very valuable for research to also have access to phenotypes
that decrease in frequency on drug treatment. If a drug strongly
reduces the frequency of certain phenotypes compared with
the background frequency observed in the control (placebo)
group, this might give hints towards novel indications for this
drug. For example, it had been noticed that selective serotonin
reuptake inhibitors (SSRIs) often have the side effect of
delayed ejaculation, or conversely, a reduced rate of premature
ejaculation compared with the background frequency. Dapox-
etine, a short-acting SSRI, is therefore now used to treat
premature ejaculation (Ashburn and Thor, 2004). A large-scale
analysis of all drugs might be able to uncover further novel
indication areas. Many side effects occur almost equally often
in placebo as in drug treatment, for example, weakness and
headache. Those side effects are either associated with the
underlying disease, or are a result of the nocebo effect: patients
who expect certain side effects are more likely to experience
these effects (Barsky et al, 2002). In contrast, a few side effects
have a median frequency for drug administration that is much
larger than placebo (Figure 3D), for example, erythema,
amenorrhea and leukopenia. Further investigation on the
nature of these side effects that cannot be induced by placebo
treatment could yield insights into the etiology of side effects
occurring during placebo treatment.
To facilitate research on drugs and their side effects, we have
created awebsite (http://sideeffects.embl.de) where users can
download the whole database and examine the side effects of
individual drugs of interest. In particular, researchers can
explore the package inserts through the concept of ‘augmented
browsing’, in which the side effect terms are highlighted and
the user can click on the highlighted terms to retrieve
additional information about proteins, chemicals and side
effects (Pafilis et al, 2009). In this way, even scientists who do
not have a background in pharmacology can easily work with
this diverse set of entities.
The database will be updated periodically with the
incorporation of new drug labels. It is available under Creative
Commons Attribution-Noncommercial-Share Alike 3.0 Li-
cense with separate licensing for commercial entities. A
snapshot of the database has been deposited as Supplementary
Information. The download files also contain information
extracted from package inserts that could not be mapped to
individual drugs, either because the particular brand name is
not in our dictionary of drugs, or because the package insert
describes a combination of drugs.
The present resource for the first time makes a set of side
effects for drugs from all indications freely available for
academic research. Although we have calculated only a few
global statistics to illustrate the potential of this resource,
future studies might investigate the relations between side
effects and chemical structure, pharmacophores, gene expres-
sion or target sharing on a molecular level. In particular, the
data about side effect frequencies should be a valuable
resource to determine the correlation between drug targets,
plasma concentrations and side effect incidence, and to
understand from a molecular point of view the observed
variability in the population to drug response and their side
effects. This knowledge will be very helpful in designing
personalizedmedicines inwhich drug treatment will be ideally
adjusted according to particular genomic, proteomic or
environmental personal features. All these venues of research
would furthermore greatly benefit from a greater availability of
data generated during clinical trials. The SPL format is a
considerable step towards making this information accessible.
Nonetheless, all relevant data that have to be shown by law on
the drug labels should be directly deposited into computer-
readable repositories to avoid loss of information.
Materials and methods
The extraction procedure is based on the method used in Campillos
et al (2008). We only include labels from public sources (which are
partly more difficult to parse because of a greater variability in
formats) and extend the set of FDA-approved drugs from 746 used in
the earlier study to 798. Although new information could be found for
97 drugs, labels for 45 drugs were not publicly available and hence
could not be included in this public resource. For example, this is the
case for hydrocodone, which is exclusively used in combination with
other drugs. Adding information for 90 non-FDA-approved drugs
yields a total of 888 drugs in the database.
Drug labels are provided by the FDA and the other sources in two
kinds of files: PDF and SPL documents. Among the five public sources
from which we compiled information (Supplementary Table 1),
Facts@FDA is the only source providing SPL documents. Analyzing
the content of PDF files is hampered by the fact that the format only
describes the coordinates of individual pieces of text, but not the
logical structure of the document, for example, paragraphs or table
rows. Besides, PDF files had to be converted to text files to be amenable
for text mining. In contrast, SPL documents are Extensible Markup
Language (XML) documents that provide information in a structured
andmachine-readableway. Both types of labels were analyzed by text-
mining tools using a dictionary of side effects derived from the UMLS
Metathesaurus. COSTART was used as seed dictionary, to which
synonyms from equivalent terms of the UMLS were added. The
sections describing the drugs’ indication areas and side effects were
used to extract terms corresponding to side effects. Terms that occur as
an indication for the drug were subsequently excluded from the drug’s
side effects to filter terms used in the adverse effect section that
actually describe the drug’s indication area (e.g., in the description of
clinical trials).
For 52% of all drugs, the sections describing adverse reactions on
the labels contain information about the frequencies of side effects.
The FDA SPL labels were amenable to a thorough analysis and exact
frequency information could be extracted from the tables detailing the
side effect frequencies by analyzing the contents of the table captions
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and cells (e.g., caption in the first row: ‘Percentages of Patients
Reporting Event’, caption in the first column: ‘anemia’, cell: ‘12’: 12%
of the patients report anemia). Although it was not possible to deduce
exact frequency information for PDF labels, standardized general
frequency ranges (‘rare’, ‘infrequent’ and ‘frequent’) could be
extracted for both label types from sections that listed the frequency
and a number of side effects (e.g.,‘frequent: headache, dizziness,y’)
Furthermore, side effects that occurred in the post-marketing phase
were also extracted from all labels. For any given drug–side effect pair,
multiple frequencies might be available, for example, from clinical
trials in different indication areas. On the website, we display all
reported frequencies to the user.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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